MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
OMCL stock logo

OMCL

Omnicell, Inc.

$38.9
-1.79
 (-4.41%)
Exchange:  NASDAQ
Market Cap:  1.769B
Shares Outstanding:  1.704M
Delayed data
Calculate OMCL Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Healthcare Information Services
   
CEO:  Randall A. Lipps
Full Time Employees:  3620
Address: 
590 East Middlefield Road
Mountain View
CA
94043
US
Website:  https://www.omnicell.com
Omnicell, Inc., founded in 1992 and headquartered in Mountain View, California (initially operating as Omnicell Technologies, Inc. until its name change in 2001), delivers advanced medication management technologies and patient adherence solutions. The company serves healthcare systems and pharmacies both domestically within the United States and globally. Its extensive portfolio of offerings includes: Clinical Workflow Automation: Omnicell provides automated solutions designed to streamline clinician tasks in patient care environments. This encompasses the XT Series automated dispensing units for medications and supplies across nursing units, clinical areas, and surgical suites. They also offer interface software to ensure smooth integration between their products and a healthcare facility’s existing information systems, alongside robotic systems for automated storage and retrieval of packaged medications. Central Pharmacy Optimization: For the central pharmacy, Omnicell offers sophisticated automation, including automated storage and retrieval platforms like the XR2 Automated Central Pharmacy System. This segment also features robotic systems and workflow management tools for IV compounding, comprehensive inventory management software, and systems for controlled substance oversight. Single-Dose Packaging for Adherence: The company develops automated technologies for filling and labeling patient-specific, single-dose medication blister packaging according to prescriptions. This includes both fully and semi-automated equipment for institutional pharmacies to ensure precise packaging, along with blister card packaging and supplies aimed at improving medication adherence, particularly in non-acute care settings. Digital Patient Engagement: Omnicell further provides EnlivenHealth Patient Engagement, a web-based platform offering various tools to interact with patients.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/04/28 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,147,1121,112,2381,184,845
Gross Profit499,929471,003508,043
EBITDA79,97990,09298,299
Operating Income-19,32933711,665
Net Income-20,37112,5312,052

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets2,226,8782,120,9601,974,720
Total Liabilities1,037,924877,647742,906
Total Stockholders Equity1,188,9541,243,3131,231,814
Total Debt614,090382,546192,390
Cash and Cash Equivalents467,972369,201196,520

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow181,094187,722127,300
Capital Expenditure-55,016-36,463-40,415
Free Cash Flow126,078151,25986,885
Net Income-20,37112,5312,052
Net Change in Cash148,144-102,365-147,582

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2028Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)1,400,914Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,437,286Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)1,419,100Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)129,587.605Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)132,952.095Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)131,269.850Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)104,949.661Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)108,307.661Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)106,628.661Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)497,999.376Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)510,928.959Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)504,464.167Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)2.300Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)2.340Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)2.260Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)2Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
1.112B  ?P/S
 (TTM)
: 
1.6
?Net Income
 (TTM)
: 
12.531M  ?P/E
 (TTM)
: 
95.38
?Enterprise Value
 (TTM)
: 
1.867B  ?EV/FCF
 (TTM)
: 
16.7
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
0.02  ?ROIC
 (TTM)
: 
0.01
?Net Debt
 (TTM)
: 
-16068000  ?Debt/Equity
 (TTM)
: 
0.16
?P/B
 (TTM)
: 
1.55  ?Current Ratio
 (TTM)
: 
1.46

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
20.05Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates OMCL intrinsic value between $48.12 – $133.50 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about OMCL valuation

Is Omnicell, Inc. (OMCL) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Omnicell, Inc. (OMCL) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is OMCL a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether OMCL trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is OMCL’s P/E ratio?

You can see OMCL’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for OMCL?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is OMCL a good long-term investment?

Whether OMCL fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

OMCL

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-4.41
MARKETSnap

Trading Metrics:

Open: —   Previous Close: —
Day Low: —   Day High: —
Year Low:    Year High: 
Price Avg 50:    Price Avg 200: 
Volume:    Average Volume: 

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Omnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Omnicell (OMCL) Up 0.1% Since Last Earnings Report: Can It Continue?
Omnicell Stock Surges 57.3% in a Year: What's Driving It?
Omnicell, Inc. (OMCL) Shareholder/Analyst Call Prepared Remarks Transcript
Omnicell (OMCL) is a Great Momentum Stock: Should You Buy?
Surging Earnings Estimates Signal Upside for Omnicell (OMCL) Stock

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read